MARKET

AVDL

AVDL

Avadel
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.65
-0.01
-0.13%
Opening 09:30 05/06 EDT
OPEN
7.65
PREV CLOSE
7.66
HIGH
7.65
LOW
7.65
VOLUME
857
TURNOVER
--
52 WEEK HIGH
10.33
52 WEEK LOW
4.830
MARKET CAP
447.43M
P/E (TTM)
-38.9908
1D
5D
1M
3M
1Y
5Y
Cowen And Company, Llc Buys iShares iBoxx USD High Yield Corporate Bond ETF, SPDR Biotech ETF, ...
GuruFocus News · 2d ago
Nocturnal Polyuria Treatment Market Size, Share, Trends, Analysis and Forecast 2027
Apr 29, 2021 (Market Insight Reports) -- The report on Nocturnal Polyuria Treatment provides the clients with a comprehensive analysis of crucial driving...
Market Insight Reports · 6d ago
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th
DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplex...
GlobeNewswire · 04/29 12:00
Restless Leg Syndrome Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast
Apr 23, 2021 (AB Digital via COMTEX) -- Restless legs syndrome (RLS), also called Willis-Ekbom Disease, causes unpleasant or uncomfortable sensations in the...
ABNewswire · 04/23 19:08
Clinical Nutrition Market – Detailed Analysis of Current Industry Figures with Forecasts Growth By 2028
Apr 20, 2021 (Market Insight Reports) -- Selbyville, Delaware According to the business intelligence report titled 'GLOBAL Clinical Nutrition Market...
Market Insight Reports · 04/20 05:38
8-K: AVADEL PHARMACEUTICALS PLC
(EDGAR Online via COMTEX) -- 0001012477 false 0001012477 2021-04-17 2021-04-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/19 13:13
Avadel's Formulated Sodium Oxybate Shows Improved Sleepiness, Sleep Quality In Narcolepsy Patients
Benzinga · 04/19 11:05
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting
GlobeNewswire · 04/17 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVDL. Analyze the recent business situations of Avadel through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVDL stock price target is 18.56 with a high estimate of 23.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 46.96M
% Owned: 80.30%
Shares Outstanding: 58.49M
TypeInstitutionsShares
Increased
21
1.82M
New
23
5.09M
Decreased
21
1.29M
Sold Out
19
2.11M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.68%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Non-Executive Chairman/Independent Director
Geoffrey Glass
Chief Executive Officer/Chief Operating Officer/Executive Vice President/Director
Gregory Divis
Chief Financial Officer
Thomas McHugh
Other
Richard Kim
Independent Director
Eric Ende
Independent Director
Mark McCamish
Independent Director
Linda Palczuk
Independent Director
Peter Thornton
No Data
  • All
  • Financials
  • Insiders
More
About AVDL
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

Webull offers kinds of Avadel Pharmaceuticals PLC (ADR) stock information, including NASDAQ:AVDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVDL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVDL stock methods without spending real money on the virtual paper trading platform.